Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089274 | 0.98 | CYP19A1 (0.45) | CYP19A1SCN5ASLC6A3SIGMAR1TBXA2R | |
| SCHEMBL6902789 | 0.98 | CYP19A1 (0.45) | CYP19A1SCN5ASLC6A3SIGMAR1TBXA2R | |
| SCHEMBL5864161 | 0.94 | CYP19A1 (0.47) | CYP19A1SCN5ASLC6A3TBXA2RLMNA | |
| SCHEMBL3688208 | 0.85 | CYP19A1 (0.44) | CYP19A1SCN5ALMNAHTTNPSR1 | |
| SCHEMBL8120558 | 0.80 | SIGMAR1 (0.59) | CYP19A1SIGMAR1KCNH2EPHX2 | |
| Fluorobenzene SCHEMBL7807000 | 0.80 | SLC18A3 (0.46) | SLC6A3SIGMAR1HTT | |
| SCHEMBL7789674 | 0.79 | CYP19A1 (0.46) | CYP19A1SCN5ASLC6A3SIGMAR1TBXA2R | |
| SCHEMBL14299747 | 0.79 | CYP19A1 (0.46) | CYP19A1SCN5ASLC6A3TBXA2RCACNA1B | |
| SCHEMBL22028771 | 0.79 | HRH1 (0.57) | CYP19A1SCN5ASLC6A3TBXA2RCACNA1B | |
| SCHEMBL7331536 | 0.79 | CYP19A1 (0.46) | CYP19A1SCN5ASLC6A3TBXA2RCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | UNIV TEXAS TECH SYSTEM (US) | 2025-05-15 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-11225459-B2 | Substituted bisphenylalkylurea compounds and methods | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200181069-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2020033909-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032924-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-0727421-B1 | Agents for improving sleep | JANSSEN PHARMACEUTICA NV (BE) | 2001-10-24 | — | — | EP | disclosed |
| EP-0727421-A1 | Agents for improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-21 | — | — | EP | disclosed |
| US-5026853-A | Sleep and cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-25 | — | — | US | disclosed |
| US-4968684-A | N-ARYL-PIPERAZINEALKANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-06 | — | — | US | disclosed |
| US-4880808-A | SEDATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-11-14 | — | — | US | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TP53, ULK1, TFEB | CYP19A1 2286/4885SCN5A 4727/4885SLC6A3 1928/4885 |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | CYP19A1 2286/4885SCN5A 4727/4885SLC6A3 1928/4885 |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | CYP19A1 2414/4885SCN5A 4791/4885SLC6A3 2908/4885 |
| US-11225459-B2 | Substituted bisphenylalkylurea compounds and methods | HTR3B, HTR3A, HTR3C | CYP19A1 4425/4885SCN5A 4432/4885SLC6A3 4/4885 |
| US-20200181069-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | HTR3B, HTR3A, HTR3C | CYP19A1 4425/4885SCN5A 4432/4885SLC6A3 4/4885 |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | CYP19A1 2286/4885SCN5A 4727/4885SLC6A3 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.